Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2014

01.02.2014 | Original article

The QUIRO Study (assurance of quality and innovation in radiooncology): methodology, instruments and practices

verfasst von: J. Dunst, N. Willich, H. Sack, R. Engenhart-Cabillic, V. Budach, Dr. W. Popp

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The QUIRO study aimed to establish a secure level of quality and innovation in radiation oncology. Over 6 years, 27 specific surveys were conducted at 24 radiooncological departments. In all, 36 renowned experts from the field of radiation oncology (mostly head physicians and full professors) supported the realization of the study.

Methods

A salient feature of the chosen methodological approach is the “process” as a means of systematizing diversified medical–technical procedures according to standardized criteria. On the one hand, “processes” as a tool of translation are adapted for creating and transforming standards into concrete clinical and medical actions; on the other hand, they provide the basis for standardized instruments and methods to determine the required needs of physicians, staff, and equipment. In the foreground of the collection and measurement of resource requirements were the processes of direct service provision which were subdivided into modules for reasons of clarity and comprehensibility. Overhead tasks (i.e., participation in quality management) were excluded from the main study and examined in a separate survey with appropriate methods.

Results

After the exploration of guidelines, tumor- or indication-specific examination and treatment processes were developed in expert workshops. Moreover, those specific modules were defined which characterize these entities and indications in a special degree. Afterwards, these modules were compiled according to their time and resources required in the “reference institution”, i.e., in specialized and as competent recognized departments (mostly from the university area), by various suitable survey methods.

Conclusion

The significance of the QUIRO study and the validity of the results were optimized in a process of constant improvements and comprehensive checks. As a consequence, the QUIRO study yields representative results concerning the resource requirement for specialized, qualitatively and technologically highly sophisticated radiooncologic treatment in Germany
Literatur
1.
Zurück zum Zitat Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. Strahlenther Onkol 188:113–119PubMedCrossRef Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. Strahlenther Onkol 188:113–119PubMedCrossRef
2.
Zurück zum Zitat Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef
3.
Zurück zum Zitat Davenport TH, Short JE (1990) The new industrial engineering, information technology and business process redesign. Sloan Manage Rev 31:11–27 Davenport TH, Short JE (1990) The new industrial engineering, information technology and business process redesign. Sloan Manage Rev 31:11–27
4.
Zurück zum Zitat De Luc K (2001) Developing care pathways—the handbook. Oxford De Luc K (2001) Developing care pathways—the handbook. Oxford
5.
Zurück zum Zitat European Association of Business Process Management (2009) Business process management. Gießen European Association of Business Process Management (2009) Business process management. Gießen
6.
Zurück zum Zitat Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. Strahlenther Onkol 187:5–11CrossRef Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. Strahlenther Onkol 187:5–11CrossRef
7.
Zurück zum Zitat Harkleroad A, Schirf D, Volpe J et al (2000) Critical pathway development: an integrative literature review. Am J Occup Ther 54(2):148–154PubMedCrossRef Harkleroad A, Schirf D, Volpe J et al (2000) Critical pathway development: an integrative literature review. Am J Occup Ther 54(2):148–154PubMedCrossRef
8.
Zurück zum Zitat Institute of Physics and Engineering in Medicine (2002) Guidelines for the provision of a physics service to radiotherapy. IPEM document Institute of Physics and Engineering in Medicine (2002) Guidelines for the provision of a physics service to radiotherapy. IPEM document
9.
Zurück zum Zitat International Atomic Energy Agency (2008) Setting up a radiotherapy program, clinical, medical physics, radiation protection and safety aspects. IAEA, Austria International Atomic Energy Agency (2008) Setting up a radiotherapy program, clinical, medical physics, radiation protection and safety aspects. IAEA, Austria
10.
Zurück zum Zitat Johanson HJ, McHugh P, Pendlebury AJ, Wheeler WA II (1993) Business process reengineering, breakpoint strategies for market dominance. Chichester Johanson HJ, McHugh P, Pendlebury AJ, Wheeler WA II (1993) Business process reengineering, breakpoint strategies for market dominance. Chichester
11.
Zurück zum Zitat Katterhagen G (1996) Physician compliance with outcome-based guidelines and clinical pathways in oncology. Oncology 10(11):113–121PubMed Katterhagen G (1996) Physician compliance with outcome-based guidelines and clinical pathways in oncology. Oncology 10(11):113–121PubMed
12.
Zurück zum Zitat Kobeissi BJ, Gupta M, Perez CA et al (1998) Physician resource utilization in radiation oncology, a model based on management of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 40:593–603PubMedCrossRef Kobeissi BJ, Gupta M, Perez CA et al (1998) Physician resource utilization in radiation oncology, a model based on management of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 40:593–603PubMedCrossRef
13.
Zurück zum Zitat Kohlbacher M (2010) The effects of process orientation, a literature review. Bus Process Manag J 16:135–152CrossRef Kohlbacher M (2010) The effects of process orientation, a literature review. Bus Process Manag J 16:135–152CrossRef
14.
Zurück zum Zitat Mazeron JJ, Mornex F, Eschwege F et al (2008) Qualité en radiothérapie, les actions de la société française de radiothérapie oncologique (SFRO), Increasing quality and safety of external radiation treatments, actions of the french society of radiation oncology (SFRO). Cancer Radiotherapy 12:601–605CrossRef Mazeron JJ, Mornex F, Eschwege F et al (2008) Qualité en radiothérapie, les actions de la société française de radiothérapie oncologique (SFRO), Increasing quality and safety of external radiation treatments, actions of the french society of radiation oncology (SFRO). Cancer Radiotherapy 12:601–605CrossRef
15.
Zurück zum Zitat Nathan RE, Hochman J, Becker R et al (2000) Critical pathways: a review. Circulation (AHA Scientific Statement) 101:461–465 Nathan RE, Hochman J, Becker R et al (2000) Critical pathways: a review. Circulation (AHA Scientific Statement) 101:461–465
16.
Zurück zum Zitat Panella M, Marchisio S, Di Stanislao F (2003) Reducing clinical variations with clinical pathways, do pathways work? Int J Qual Health Care 15:509–521PubMedCrossRef Panella M, Marchisio S, Di Stanislao F (2003) Reducing clinical variations with clinical pathways, do pathways work? Int J Qual Health Care 15:509–521PubMedCrossRef
17.
Zurück zum Zitat Portaluri M, Fucilli FI, Gianicolo EA et al (2010) Collection and evaluation of incidents in a radiotherapy department, a reactive risk analysis. Strahlenther Onkol 186:693–699PubMedCrossRef Portaluri M, Fucilli FI, Gianicolo EA et al (2010) Collection and evaluation of incidents in a radiotherapy department, a reactive risk analysis. Strahlenther Onkol 186:693–699PubMedCrossRef
18.
Zurück zum Zitat Purdy PW, Procter HD, Wasserman TW (1993) Cost accounting in radiation oncology, a computer-based model for reimbursement. Int J Radiat Oncol Biol Phys 25:895–906PubMedCrossRef Purdy PW, Procter HD, Wasserman TW (1993) Cost accounting in radiation oncology, a computer-based model for reimbursement. Int J Radiat Oncol Biol Phys 25:895–906PubMedCrossRef
19.
Zurück zum Zitat Renholm M, Leino-Kilpi H, Suominen T (2002) Critical pathways: a systematic review. J Nurs Adm 32(4):196–202PubMedCrossRef Renholm M, Leino-Kilpi H, Suominen T (2002) Critical pathways: a systematic review. J Nurs Adm 32(4):196–202PubMedCrossRef
20.
Zurück zum Zitat Smith, TJ, Hillner BE (2001) Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 11:2886–2897 Smith, TJ, Hillner BE (2001) Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 11:2886–2897
21.
Zurück zum Zitat Swenson KD (2010) Mastering the unpredictable. Tampa Swenson KD (2010) Mastering the unpredictable. Tampa
22.
Zurück zum Zitat Van Herck P, Vanhaecht K, Sermeus W (2004) Effects of clinical pathways: do they work? J Integr Care Pathw 8:95–105 Van Herck P, Vanhaecht K, Sermeus W (2004) Effects of clinical pathways: do they work? J Integr Care Pathw 8:95–105
23.
Zurück zum Zitat Vom Brocke J, Rosemann M (2010) Handbook on business process management, strategic alignment, governance, people and culture. Berlin Vom Brocke J, Rosemann M (2010) Handbook on business process management, strategic alignment, governance, people and culture. Berlin
24.
Zurück zum Zitat Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery. Strahlenther Onkol 188:769–776CrossRef Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery. Strahlenther Onkol 188:769–776CrossRef
25.
Zurück zum Zitat Zander K (2002) Integrated care pathways: eleven international trends. J Integr Care Pathw 6:101–107 Zander K (2002) Integrated care pathways: eleven international trends. J Integr Care Pathw 6:101–107
Metadaten
Titel
The QUIRO Study (assurance of quality and innovation in radiooncology): methodology, instruments and practices
verfasst von
J. Dunst
N. Willich
H. Sack
R. Engenhart-Cabillic
V. Budach
Dr. W. Popp
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0555-3

Weitere Artikel der Ausgabe 2/2014

Strahlentherapie und Onkologie 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.